摘要
目的:观察利伐沙班对心胸外科手术后下肢深静脉血栓患者的治疗效果。方法:选取78例心胸外科手术后下肢深静脉血栓患者作为观察对象,按照随机数字表法分为对照组与观察组,每组39例。对照组予低分子肝素钠与华法林治疗,观察组予利伐沙班治疗,比较两组临床疗效,膝关节髌骨中点上、膝关节髌骨中点下的肢围差,血浆组织型纤溶酶原激活剂(t-PA)、纤溶酶原激活抑制物-1(PAI-1)和D-二聚体(D-D)水平,以及不良反应发生率。结果:观察组临床总有效率为97.44%,高于对照组的82.05%,差异无统计学意义(P>0.05);治疗7、14 d后,两组膝关节髌骨中点上、膝关节髌骨中点下的肢围差均较治疗前减小,且观察组均小于对照组,差异有统计学意义(P<0.05);两组t-PA水平均较治疗前升高,且观察组高于对照组,两组PAI-1、D-D水平均较治疗前降低,且观察组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:利伐沙班可降低心胸外科手术后下肢深静脉血栓患者患肢肿胀程度,提高临床疗效,安全可靠。
Objective: To investigate effect of Rivaroxaban on patients with deep venous thrombosis of lower limb after cardiothoracic surgeries. Methods: 78 patients with deep venous thrombosis of lower limb after the cardiothoracic surgery in our hospital were selected as the observation objects. According to the random number table method, they were divided into control group and observation group with 39 cases in each group. The control group was treated with low molecular weight Heparin sodium and Warfarin, while the observation group was treated with rivaroxaban. The curative effects, the limb circumference differences above and below the patella center, the levels of plasma tissue plasminogen activator(t-PA), plasminogen activator inhibitor-1(PAI-1) and D-dimer(D-D) and adverse reactions were compared between the two groups. Results: The total effective rate of the observation group was 97.44%, which was higher than that of the control group(82.05%), and the difference was not statistically significant(P>0.05). 7 and 14 days after the treatment, the limb circumference differences above and below the patella center were smaller than those before the treatment, those of the observation group were smaller than those of the control group, and the differences were statistically significant(P<0.05). The levels of t-PA in the two groups after the treatment were higher than those before the treatment, and that of the observation group was higher than that of the control group;the PAI-1 and DD levels in the two groups were lower than those before the treatment, and those of observation group were lower than those of the control group;and the differences were statistically significant(P<0.05). Further, there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusions: Rivaroxaban can reduce the degree of swelling of the limbs of the patients with deep venous thrombosis of lower limb after the cardiothoracic surgeries and improve the clinical efficacy, and is safe and reliable.
作者
庄严
ZHUANG Yan(Department of Cardiovascular Surgery of the Central Hospital of Jiamusi City,Jiamusi 154007 Heilongjiang,China)
出处
《中国民康医学》
2019年第18期24-26,共3页
Medical Journal of Chinese People’s Health
